This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Dedalus Pharma, LLC (``Dedalus'') located in Maryland, USA.
Document
Prospective Grant of Exclusive License: The Development of Anti-CD70 Chimeric Antigen Receptors (CARs) for the Treatment of Chronic Myelogenous Leukemia
This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Cancer Institute, National Institutes of Health, Department of Health and Human Services,...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
81 FR 23737
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Prospective Grant of Exclusive License: The Development of Anti-CD70 Chimeric Antigen Receptors (CARs) for the Treatment of Chronic Myelogenous Leukemia,” thefederalregister.org (April 22, 2016), https://thefederalregister.org/documents/2016-09324/prospective-grant-of-exclusive-license-the-development-of-anti-cd70-chimeric-antigen-receptors-cars-for-the-treatment-of.